{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:40:20Z","timestamp":1790854820229,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celgene International II SARL","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Takeda France SAS","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100015756","name":"Janssen-Cilag","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Amgen SAS","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Age-adjusted lymphoma incidence rates continue to rise in France since the early 80\u2019s, although rates have slowed since 2010 and vary across subtypes. Recent improvements in patient survival in major lymphoma subtypes at population level raise new questions about patient outcomes (i.e. quality of life, long-term sequelae). Epidemiological studies have investigated factors related to lymphoma risk, but few have addressed the extent to which socioeconomic status, social institutional context (i.e. healthcare system), social relationships, environmental context (exposures), individual behaviours (lifestyle) or genetic determinants influence lymphoma outcomes, especially in the general population. Moreover, the knowledge of the disease behaviour mainly obtained from clinical trials data is partly biased because of patient selection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The REALYSA (\u201cREal world dAta in LYmphoma and Survival in Adults\u201d) study is a real-life multicentric cohort set up in French areas covered by population-based cancer registries to study the prognostic value of epidemiological, clinical and biological factors with a prospective 9-year follow-up. We aim to include 6000 patients over 4 to 5\u2009years. Adult patients without lymphoma history and newly diagnosed with one of the following 7 lymphoma subtypes (diffuse large B-cell, follicular, marginal zone, mantle cell, Burkitt, Hodgkin, mature T-cell) are invited to participate during a medical consultation with their hematologist. Exclusion criteria are: having already received anti-lymphoma treatment (except pre-phase) and having a documented HIV infection. Patients are treated according to the standard practice in their center. Clinical data, including treatment received, are extracted from patients\u2019 medical records. Patients\u2019 risk factors exposures and other epidemiological data are obtained at baseline by filling out a questionnaire during an interview led by a clinical research assistant. Biological samples are collected at baseline and during treatment. A virtual tumor biobank is constituted for baseline tumor samples. Follow-up data, both clinical and epidemiological, are collected every 6\u2009months in the first 3\u2009years and every year thereafter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This cohort constitutes an innovative platform for clinical, biological, epidemiological and socio-economic research projects and provides an opportunity to improve knowledge on factors associated to outcome of lymphoma patients in real life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>2018-A01332\u201353, ClinicalTrials.gov identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03869619\">NCT03869619<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-10433-4","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T19:02:54Z","timestamp":1614711774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the \u201cREal world dAta in LYmphoma and survival in adults\u201d (REALYSA) cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Cherblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Le Guyader-Peyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Fabbro-Peray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc-Matthieu","family":"Fornecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Morineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Labour\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fitoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Monnereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"20","key":"10433_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"6","key":"10433_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10433_CR3","volume-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 [Internet]","author":"S Le Guyader-Peyrou","year":"2019","unstructured":"Le Guyader-Peyrou S, Defossez G, Dantony E, Mounier M, Cornet E, Uhry Z, et al. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 [Internet]. 2019 [cited 2019 Jul 22]. (Les Donn\u00e9es \/ Epidemiologie). Available from: https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Rapport-Volume-2-Hemopathies-malignes-Estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-metropolitaine-entre-1990-et-2018-Juillet-2019"},{"issue":"48","key":"10433_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130\u201344.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"10433_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"9844","key":"10433_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet Lond Engl. 2012;380(9844):848\u201357.","journal-title":"Lancet Lond Engl"},{"key":"10433_CR7","volume-title":"Survie des personnes atteintes de cancer en France m\u00e9tropolitaine 1989\u20132013 - \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim Partie 2 \u2013 H\u00e9mopathies malignes [Internet]","author":"A Monnereau","year":"2016","unstructured":"Monnereau A, Uhry Z, Bossard N, Cowply-Bony A, Voirin N, Delafosse P, et al. Survie des personnes atteintes de cancer en France m\u00e9tropolitaine 1989\u20132013 - \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim Partie 2 \u2013 H\u00e9mopathies malignes [Internet]. Saint-Maurice: Sant\u00e9 Publique France; 2016. [cited 2020 Feb 24]. Available from: http:\/\/www.canceraquitaine.org\/sites\/default\/files\/ddblock\/Survie_personnes_atteintes_cancer_france_metropolitaine_1989_2013_hemopathies_malignes.pdf"},{"issue":"15","key":"10433_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: Results of EUROCARE-5 population-based study. Eur J Cancer Oxf Engl. 2015;51(15):2254\u201368.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"5","key":"10433_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258\u201365.","journal-title":"Blood."},{"issue":"14","key":"10433_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"15","key":"10433_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018 Apr 12;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"10433_CR12","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.18632\/oncotarget.14448","volume":"8","author":"C Sarkozy","year":"2017","unstructured":"Sarkozy C, Huet S, Carlton VEH, Fabiani B, Delmer A, Jardin F, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017 Jan 2;8(5):8765\u201374.","journal-title":"Oncotarget."},{"issue":"12","key":"10433_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/ajh.25288","volume":"93","author":"PA Pophali","year":"2018","unstructured":"Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, et al. The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol. 2018;93(12):1543\u201350.","journal-title":"Am J Hematol"},{"issue":"5","key":"10433_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hon.2522","volume":"36","author":"CA Thompson","year":"2018","unstructured":"Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, et al. Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol. 2018 Dec;36(5):749\u201356.","journal-title":"Hematol Oncol"},{"issue":"30","key":"10433_CR15","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1200\/JCO.2007.14.6571","volume":"26","author":"LA Anderson","year":"2008","unstructured":"Anderson LA, Pfeiffer RM, Rapkin JS, Gridley G, Mellemkjaer L, Hemminki K, et al. Survival patterns among lymphoma patients with a family history of lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Oct 20;26(30):4958\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10433_CR16","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/ijc.27944","volume":"132","author":"JF Simard","year":"2013","unstructured":"Simard JF, Baecklund F, Chang ET, Baecklund E, Hjalgrim H, Adami H-O, et al. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int J Cancer. 2013;132(11):2659\u201366.","journal-title":"Int J Cancer"},{"issue":"5","key":"10433_CR17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/bjc.2012.3","volume":"106","author":"BL Frederiksen","year":"2012","unstructured":"Frederiksen BL, Dalton SO, Osler M, Steding-Jessen M, de Nully Brown P. Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark--a nationwide study. Br J Cancer. 2012 Feb 28;106(5):988\u201395.","journal-title":"Br J Cancer"},{"issue":"6","key":"10433_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ejca.2010.11.014","volume":"47","author":"BL Frederiksen","year":"2011","unstructured":"Frederiksen BL, Brown P d N, Dalton SO, Steding-Jessen M, Osler M. Socioeconomic inequalities in prognostic markers of non-Hodgkin lymphoma: analysis of a national clinical database. Eur J Cancer Oxf Engl. 2011;47(6):910\u20137.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"12","key":"10433_CR19","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/cncr.25114","volume":"116","author":"SM Geyer","year":"2010","unstructured":"Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer. 2010 Jun 15;116(12):2993\u20133000.","journal-title":"Cancer."},{"issue":"8","key":"10433_CR20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/annonc\/mdl096","volume":"17","author":"T Battaglioli","year":"2006","unstructured":"Battaglioli T, Gorini G, Costantini AS, Crosignani P, Miligi L, Nanni O, et al. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin\u2019s lymphoma: a population-based study. Ann Oncol Off J Eur Soc Med Oncol. 2006;17(8):1283\u20139.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"5","key":"10433_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/10428190801933377","volume":"49","author":"C Bray","year":"2008","unstructured":"Bray C, Morrison DS, McKay P. Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leuk Lymphoma. 2008;49(5):917\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10433_CR22","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ijc.23205","volume":"122","author":"R Talamini","year":"2008","unstructured":"Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, et al. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer. 2008 Apr 1;122(7):1624\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"10433_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11764-009-0111-4","volume":"4","author":"X Han","year":"2010","unstructured":"Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, et al. Alcohol consumption and non-Hodgkin lymphoma survival. J Cancer Surviv Res Pract. 2010;4(2):101\u20139.","journal-title":"J Cancer Surviv Res Pract"},{"issue":"12","key":"10433_CR24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00432-009-0618-0","volume":"135","author":"J Ji","year":"2009","unstructured":"Ji J, F\u00f6rsti A, Sundquist J, Lenner P, Hemminki K. Survival in non-Hodgkin\u2019s lymphoma by histology and family history. J Cancer Res Clin Oncol. 2009 Dec;135(12):1711\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10433_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2093","volume":"2","author":"S Lamure","year":"2019","unstructured":"Lamure S, Carles C, Aquereburu Q, Quittet P, Tchernonog E, Paul F, et al. Association of Occupational Pesticide Exposure with Immunochemotherapy Response and Survival among Patients with Diffuse Large B-cell lymphoma. JAMA Netw Open. 2019 Apr 5;2(4):e192093.","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10433_CR26","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2015-04-537498","volume":"126","author":"JR Cerhan","year":"2015","unstructured":"Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015 Nov 12;126(20):2265\u201373.","journal-title":"Blood."},{"issue":"33","key":"10433_CR27","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1200\/JCO.2014.60.2573","volume":"33","author":"H Ghesquieres","year":"2015","unstructured":"Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, et al. Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with Immunochemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Nov 20;33(33):3930\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10433_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014 Feb 4;110(3):551\u20135.","journal-title":"Br J Cancer"},{"issue":"23","key":"10433_CR29","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016 Dec 8;375(23):2293\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"10433_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7\u20138","key":"10433_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bulcan.2018.11.016","volume":"106","author":"A Cowppli-Bony","year":"2019","unstructured":"Cowppli-Bony A, Colonna M, Ligier K, Jooste V, Defossez G, Monnereau A, et al. Descriptive epidemiology of cancer in metropolitan France: Incidence, survival and prevalence. Bull Cancer (Paris). 2019;106(7\u20138):617\u201334.","journal-title":"Bull Cancer (Paris)"},{"issue":"Supplement_1","key":"10433_CR32","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1182\/blood-2019-129204","volume":"134","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Rossi C, Cherblanc F, Le Guyader S, Bijou F, Sujobert P, et al. A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. Blood. 2019;134(Supplement_1):4762.","journal-title":"Blood"},{"issue":"8","key":"10433_CR33","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(8):2166\u201372.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10433_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","volume":"27","author":"L van de Poll-Franse","year":"2018","unstructured":"van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, et al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res. 2018;27(2):333\u201345.","journal-title":"Qual Life Res"},{"issue":"4","key":"10433_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/0265407587044007","volume":"4","author":"IG Sarason","year":"1987","unstructured":"Sarason IG, Sarason BR, Shearin EN, Pierce GR. A brief measure of social support: practical and theoretical implications. J Soc Pers Relatsh. 1987;4(4):497\u2013510.","journal-title":"J Soc Pers Relatsh"},{"issue":"3","key":"10433_CR36","first-page":"41","volume":"48","author":"M Bruchon-Schweitzer","year":"2003","unstructured":"Bruchon-Schweitzer M, Rascle N, Cousson-G\u00e9lie F, Bidan-Fortier C, Sifakis Y, Constant A. Le questionnaire de soutien social de Sarason (SSQ6). Une adaptation fran\u00e7aise. Psychol Fr. 2003;48(3):41\u201353.","journal-title":"Psychol Fr"},{"issue":"8","key":"10433_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00420-008-0384-3","volume":"82","author":"J Siegrist","year":"2009","unstructured":"Siegrist J, Wege N, P\u00fchlhofer F, Wahrendorf M. A short generic measure of work stress in the era of globalization: effort-reward imbalance. Int Arch Occup Environ Health. 2009 Aug;82(8):1005\u201313.","journal-title":"Int Arch Occup Environ Health"},{"issue":"18","key":"10433_CR38","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","volume":"35","author":"C Laurent","year":"2017","unstructured":"Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadi\u00e9 M, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath network. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Jun 20;35(18):2008\u201317.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10433_CR39","volume-title":"Estimations r\u00e9gionales et d\u00e9partementales de l\u2019incidence et de la mortalit\u00e9 par cancer en France, 2007\u20132016. Mat\u00e9riel et M\u00e9thodes","author":"E Chatignoux","year":"2019","unstructured":"Chatignoux E, Remontet L, Colonna M, Grosclaude P, Cariou M, Billot-Grasset A, et al. Estimations r\u00e9gionales et d\u00e9partementales de l\u2019incidence et de la mortalit\u00e9 par cancer en France, 2007\u20132016. Mat\u00e9riel et M\u00e9thodes. Saint-Maurice: Sant\u00e9 Publique France; 2019. [cited 2020 Apr 20]. Available from: \/maladies-et-traumatismes\/cancers\/estimations-regionales-et-departementales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-2007-2016"},{"key":"10433_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data. Extending the Cox model","author":"GP Therneau","year":"2000","unstructured":"Therneau GP. Modeling survival data. Extending the Cox model. New-York: Springer; 2000. (Statistics for Biology and Health)"},{"issue":"5","key":"10433_CR41","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/ije\/dyy138","volume":"47","author":"C Infante-Rivard","year":"2018","unstructured":"Infante-Rivard C, Cusson A. Reflection on modern methods: selection bias\u2014a review of recent developments. Int J Epidemiol. 2018 Oct 1;47(5):1714\u201322.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10433_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","volume":"15","author":"MA Hern\u00e1n","year":"2004","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S, Robins JM. A structural approach to selection bias. Epidemiol Camb Mass. 2004;15(5):615\u201325.","journal-title":"Epidemiol Camb Mass"},{"issue":"3","key":"10433_CR43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","volume":"56","author":"JM Robins","year":"2000","unstructured":"Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000 Sep;56(3):779\u201388.","journal-title":"Biometrics."},{"issue":"4","key":"10433_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/aogs.13319","volume":"97","author":"EA Nohr","year":"2018","unstructured":"Nohr EA, Liew Z. How to investigate and adjust for selection bias in cohort studies. Acta Obstet Gynecol Scand. 2018 Apr;97(4):407\u201316.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"10433_CR45","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/ije\/dyx119","volume":"46","author":"JR Cerhan","year":"2017","unstructured":"Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, et al. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017;46(6):1753\u20131754i.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10433_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2141.2009.08010.x","volume":"148","author":"A Smith","year":"2010","unstructured":"Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A. The Haematological malignancy research network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol. 2010;148(5):739\u201353.","journal-title":"Br J Haematol"},{"issue":"3","key":"10433_CR47","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ije\/dyy044","volume":"47","author":"A Smith","year":"2018","unstructured":"Smith A, Howell D, Crouch S, Painter D, Blase J, Wang H-I, et al. Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. Int J Epidemiol. 2018;47(3):700\u2013700g.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10433_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3324\/haematol.2016.152918","volume":"102","author":"S Le Guyader-Peyrou","year":"2017","unstructured":"Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadi\u00e9 M, Troussard X, Monnereau A. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica. 2017;102(3):584\u201392.","journal-title":"Haematologica."},{"issue":"16","key":"10433_CR49","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, Jais J-P, Habermann TM, Thompson CA, et al. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(16):1603\u201310.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10433_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00432-017-2529-9","volume":"144","author":"A Augustin","year":"2018","unstructured":"Augustin A, Le Gouill S, Gressin R, Bertaut A, Monnereau A, Woronoff A-S, et al. Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. J Cancer Res Clin Oncol. 2018 Apr;144(4):629\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10433_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjh.15170","volume":"181","author":"A Smith","year":"2018","unstructured":"Smith A, Roman E, Appleton S, Howell D, Johnson R, Burton C, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological malignancy research network (HMRN). Br J Haematol. 2018;181(2):215\u201328.","journal-title":"Br J Haematol"},{"issue":"3","key":"10433_CR52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/bjh.15965","volume":"186","author":"TC El-Galaly","year":"2019","unstructured":"El-Galaly TC, Cheah CY, Villa D. Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. Br J Haematol. 2019 Aug;186(3):409\u201319.","journal-title":"Br J Haematol"},{"issue":"3","key":"10433_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005984","volume":"13","author":"KJ Ruddy","year":"2020","unstructured":"Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, et al. Utilization of cardiac surveillance tests in survivors of breast Cancer and lymphoma after Anthracycline-based chemotherapy. Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e005984.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"31","key":"10433_CR54","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","volume":"32","author":"CA Thompson","year":"2014","unstructured":"Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Nov 1;32(31):3506\u201312.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10433_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjh.13943","volume":"173","author":"LH Jakobsen","year":"2016","unstructured":"Jakobsen LH, Hutchings M, de Nully BP, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173(2):236\u201344.","journal-title":"Br J Haematol"},{"issue":"5","key":"10433_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood-2016-08-685073","volume":"129","author":"JB Cohen","year":"2017","unstructured":"Cohen JB, Behera M, Thompson CA, Flowers CR. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood. 2017;129(5):561\u20134.","journal-title":"Blood"},{"issue":"11","key":"10433_CR57","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e9res H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016 Nov;91(11):1096\u2013101.","journal-title":"Am J Hematol"},{"issue":"9","key":"10433_CR58","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1200\/JCO.18.01652","volume":"37","author":"JL Biccler","year":"2019","unstructured":"Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown P d N, Jakobsen LH, et al. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(9):703\u201313.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10433_CR59","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","volume":"34","author":"G Hapgood","year":"2016","unstructured":"Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, et al. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(21):2493\u2013500.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10433_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017;171(2):481\u2013494.e15.","journal-title":"Cell"},{"issue":"5","key":"10433_CR61","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"23","key":"10433_CR62","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood-2014-04-568766","volume":"123","author":"CR Flowers","year":"2014","unstructured":"Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood. 2014 Jun 5;123(23):3530\u20131.","journal-title":"Blood."},{"key":"10433_CR63","doi-asserted-by":"publisher","unstructured":"Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung Cancer patients. J Natl Cancer Inst. 2017;109(9).\u00a0https:\/\/doi.org\/10.1093\/jnci\/djx029.","DOI":"10.1093\/jnci\/djx029"},{"issue":"4","key":"10433_CR64","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ije\/dys223","volume":"42","author":"KJ Rothman","year":"2013","unstructured":"Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013 Aug 1;42(4):1012\u20134.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10433_CR65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ije\/dyt271","volume":"43","author":"L Richiardi","year":"2014","unstructured":"Richiardi L, Pizzi C, Pearce N. Representativeness. Int J Epidemiol. 2014 Apr 1;43(2):632\u20133.","journal-title":"Int J Epidemiol"},{"key":"10433_CR66","unstructured":"International Lymphoma Epidemiology Consortium [Internet]. [cited 2020 Jan 27]. Available from: https:\/\/epi.grants.cancer.gov\/InterLymph\/#publications"},{"issue":"5","key":"10433_CR67","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","volume":"15","author":"D Chihara","year":"2015","unstructured":"Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015 May;15(5):531\u201344.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"48","key":"10433_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jncimonographs\/lgu005","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, et al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):1\u201314.","journal-title":"J Natl Cancer Inst Monogr."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-10433-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T19:04:29Z","timestamp":1675019069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-10433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["10433"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-10433-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is performed according to the declaration of Helsinki, and national laws and regulations for RIPH2 studies. The REALYSA study was approved by a French ethics committee (CPP Ouest II \u2013 file number: 2018\/46) and by the National Commission for data protection and freedom of information (CNIL \u2013 decision number: DR-2018-238)). Written informed consent is obtained from patients before any data collection. A specific signed consent form is also obtained from each patient willing to participate to genetic studies that may be conducted on blood samples. Patients are free to refuse to participate, or to withdraw from the study at any time. Collected data are anonymous and secure data management systems are used. Any substantial change of the protocol (e.g. number of centers, number of collected blood samples) will be validated by the ethics committee before implementation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The study is currently funded by several commercial organizations (Roche, Takeda, Janssen, Amgen, Celgene).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}